^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

IMPT-314

i
Other names: IMPT-314, anti-CD19/CD20 CAR-T cell therapy, CD19-CD20 bi-specific CART cell therapy, CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR)-T
Company:
ImmPACT Bio, UCLA Jonsson Comprehensive Cancer Center
Drug class:
CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy
Related drugs: